SDGRNasdaqPharmaceutical PreparationsUS GAAP · USD

Schrodinger, Inc.

Schrodinger, Inc. develops computational software used to model molecules and support drug discovery for biopharmaceutical companies, academic researchers, and selected materials science users. The company also pursues proprietary drug discovery programs that use the same physics-based platform to identify and optimize new therapeutic candidates.

Kysy yhtiöstä
Liikevaihto256milj. USD
+23,3 %v/v
Liikevoitto (EBIT)−167milj. USD
+20,3 %v/v
EBIT-marginaali−65,2%
+35,6 %-yks.v/v
Nettotulos−103milj. USD
+44,8 %v/v
Vapaa kassavirta12,5milj. USD
+107,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−300−200−1000100200300milj. USD2020: 108 milj. USD2020: EBIT −61 milj. USD20202021: 138 milj. USD2021: EBIT −111 milj. USD20212022: 181 milj. USD2022: EBIT −147 milj. USD20222023: 217 milj. USD2023: EBIT −177 milj. USD20232024: 208 milj. USD2024: EBIT −209 milj. USD20242025: 256 milj. USD2025: EBIT −167 milj. USD2025256−167
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Schrodinger, Inc.

Liiketoiminta

Osuus liikevaihdosta
Software solutions70 %

Computational tools used to accelerate molecule discovery, design, and optimization.

Drug discovery collaborations25 %

Partner-funded discovery programs with milestones, research funding, and related services.

Professional services3 %

Ad hoc scientific and technical services supporting customer deployments and workflows.

Software contribution revenue2 %

Non-reciprocal funding tied to specific platform expansion initiatives.

Tuotteet

Raportoitu · osuus liikevaihdosta
71,7%17,6%10,7%FY2025100 %
  • Revenue From Contract with Customer Before Software Contribution71,7 %
  • Hosted Software17,6 %
  • Maintenance10,7 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Schrodinger sells primarily to pharmaceutical and biotechnology companies that use its software to speed early-stage research and improve decision-making in discovery programs. It also serves academic institutions worldwide and a growing set of materials science customers that use the platform for simulation and design workflows.

Large pharmaceutical companies

Buy enterprise software licenses to support target identification, design, and optimization across discovery teams.

Biotechnology companies

Use the platform for discovery workflows and to access advanced modeling capabilities without building them internally.

Academic institutions

Use the software for research and training, helping broaden adoption and scientific familiarity.

Materials science customers

Apply the platform to simulation and design problems outside life sciences.

Drug discovery collaborators

Provide research funding and milestone-based payments for partnered therapeutic programs.

Strategia

Schrodinger’s strategy is to expand adoption of its computational platform across drug discovery and adjacent scientific markets while deepening usage within large pharma accounts. It also advances proprietary drug discovery programs selectively, using partnerships, out-licensing, or internal development where appropriate to maximize value from its platform and pipeline.

Grow software penetration in large pharma and biotechLyhyt aikaväli

Enterprise adoption drives recurring license revenue and expands platform usage across discovery teams.

Broaden use cases beyond life sciencesKeskipitkä aikaväli

Materials science expands the addressable market and reduces dependence on drug discovery alone.

Advance proprietary programs through partnershipsKeskipitkä aikaväli

Partnerships can fund development and reduce capital intensity while preserving upside.

Maantiede

Q1/2026

Schrodinger operates globally, with direct sales coverage across the United States, the European Union, the United Kingdom, Japan, India, and South Korea. It also uses distributors in other markets, including China, which broadens reach but adds cross-border commercial and regulatory complexity.

USA61 %
EMEA39 %
Other countries (US filing)0,6 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The business depends on retaining and expanding a relatively concentrated base of pharmaceutical customers, so competitive displacement or lower renewal rates would pressure software growth. Its proprietary drug discovery efforts also carry scientific, regulatory, and financing risk, while international operations expose the company to cross-border execution and compliance challenges.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Capital needs and dilution risk1Customer retention and expansion risk2Competition from AI and internal discovery platforms3Clinical and preclinical program failure4International operating risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Capital needs and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea

    The company may need external financing to support software development and drug discovery activities.

    Kohdistuu: Corporate funding

  2. Customer retention and expansion riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    A meaningful share of software revenue comes from a limited number of large commercial accounts, so churn or downsizing would affect recurring revenue.

    Kohdistuu: Commercial software cohort

  3. Competition from AI and internal discovery platformsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Pharma companies can build tools internally or adopt alternative AI-based discovery solutions.

    Kohdistuu: Software and drug discovery

  4. Clinical and preclinical program failureVaikutus: KorkeaTodennäköisyys: Matala

    Proprietary assets depend on scientific success, regulatory progress, and partner interest.

    KohdistuuSGR-1505SGR-3515Other programs
  5. International operating riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Global sales, distributors, and cross-border customers create legal, tax, and execution complexity.

    KohdistuuEuropeAsiaChina
Kysy Clarifolta: Schrodinger, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for software and collaborations

Different contract types require different timing and allocation judgments, affecting reported revenue and comparability.

Vaikutus: Software licenses, collaboration milestones, and contribution funding

Variable consideration and progress measurement

Management must estimate the constraint on variable consideration and the extent of progress on collaboration work.

Vaikutus: Drug discovery revenue timing

Fair value measurement of equity investments

Changes in the value of strategic investments can move other income and create volatility outside core operations.

Vaikutus: Other income (expense)

Quarterly revenue timing

License renewals, milestone events, and ad hoc services can shift revenue between periods.

Vaikutus: Period-to-period comparability

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Shuttle Pharmaceuticals Holdings, Inc.

SHPH · Pharmaceutical Preparations

Pfizer, Inc

PFE · Pharmaceutical Preparations

MapLight Therapeutics, Inc.

MPLT · Pharmaceutical Preparations

Black Diamond Therapeutics, Inc.

BDTX · Biological Products, (No Diagnostic Substances)

Absci Corp

ABSI · Services-Commercial Physical & Biological Research

OmniAb, Inc.

OABIW · Services-Commercial Physical & Biological Research

Päivitetty: 24.9.2026

Schrodinger, Inc. (SDGR) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo